source
- MapLight Therapeutics' mid-stage schizophrenia trial shows modest improvement but shares plunge two-thirdsMapLight Therapeutics announced that its experimental schizophrenia drug met its primary endpoint in a mid-stage study, delivering an average 4.5‑point reduction on the PANSS symptom scale after fi…
- Vertex and AbCellera team up to develop next-generation T-cell engagers for autoimmune diseasesVertex Pharmaceuticals has entered a partnership with AbCellera to create next-generation T-cell engagers aimed at autoimmune diseases. AbCellera will receive an upfront payment of $28 million, wit…